Product Details
| Product Name:
Lucanthone |
CAS No.:
479-50-5 |
| Purity:
99.92% |
Supply Ability:
10g |
| Release date:
2026/09/10 |
Product Introduction
Bioactivity
| Name | Lucanthone |
| Description | Lucanthone (Lucanthonum) is an inhibitor of Apurinic endonuclease-1 (APE-1). |
| Cell Research | Cell viability is assessed by MTT assay. Cells are seeded into 96-well microculture plates at 10,000 cells per well and allowed to attach for 24 h. Cells are then treated with Lucanthone (0, 0.5, 1, 5, 10, 20 and 40 μM), Chloroquine, Vorinostat, or combinations for 72 h. Following drug treatment, MTT is added and cell viability is quantified using a BioTek microplate reader. Effects on cell viability are also determined by measuring ATP levels using the ATPlite assay system and by trypan blue exclusion. Pro-apoptotic effects following in vitro drug exposure are quantified by propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS) analysis of sub-G0/G1 DNA content[2] |
| In vitro | Lucanthone, an innovative autophagy inhibitor, induces apoptosis through cathepsin D activation and has been evaluated for its anticancer efficacy via MTT assay. Demonstrating a consistent reduction in viability across seven breast cancer cell lines, Lucanthone surpasses Chloroquine (CQ) in potency, evidenced by a significantly lower mean IC50 of 7.2 μM compared to 66 μM for CQ. Further validation through ATPlite assay and trypan blue exclusion in two representative cell lines (MDA-MB-231 and BT-20) confirms these findings. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 6 mg/mL (17.62 mM), Suspension.
DMSO : 60 mg/mL (176.22 mM), Sonication is recommended.
|
| Keywords | RNASynthesis | RNA Synthesis | Lucanthone | Inhibitor | inhibit | DNASynthesis | DNA Synthesis | Autophagy | APE1 |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Guanidine hydrochloride | Hydroxychloroquine | 2-Amino-2-methyl-1-propanol | Doxycycline | Fenpyroximate | Paeonol | Thymidine | Naringin | Alginic acid |
| Related Compound Libraries | Bioactive Compounds Library Max | Failed Clinical Trials Compound Library | Anti-Parasitic Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Human Metabolite Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States